Clinical trial
Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of…
NCT00232310 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00232310 |
|---|---|
| Title | Double Blind Placebo COntrolled Dose Ranging studY of the eFficacy and safEty of SSR149744c 300 or 600 mg for the Conversion of Atrial Fibrillation / fluttEr |
| Official title | Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744C 300 or 600 mg for the Conversion of Atrial Fibrillation / Flutter |
| Acronym | CORYFEE |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation, Atrial Flutter |
| Intervention type | Drug |
| Interventions | CELIVARONE (SSR149744C) |
| Enrollment | 150 |
| Start date | Oct 1, 2005 |
| Primary completion | Apr 1, 2006 |
| Completion | Apr 1, 2006 |
| First posted | Oct 4, 2005 |
| Last update posted | May 8, 2012 |
| Countries | Canada, Czechia, France, Germany, Hungary, Italy, Netherlands, Portugal, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: